The Most Important Facts About Royalty Pharma

By Chris Stiles • Sunday, February 09 15:08 • Permanent Link

Royalty Pharma logged a 1.1% change during today's afternoon session, and is now trading at a price of $31.73 per share. The S&P 500 index moved -1.0%. RPRX's trading volume is 3,393,408 compared to the stock's average volume of 3,630,990.

Royalty Pharma trades -22.04% away from its average analyst target price of $40.7 per share. The 9 analysts following the stock have set target prices ranging from $28.0 to $51.0, and on average have given Royalty Pharma a rating of buy.

If you are considering an investment in RPRX, you'll want to know the following:

Royalty Pharma has moved 9.2% over the last year, and the S&P 500 logged a change of 20.0%
Based on its trailing earnings per share of 2.54, Royalty Pharma has a trailing 12 month Price to Earnings (P/E) ratio of 12.5 while the S&P 500 average is 29.3
RPRX has a forward P/E ratio of 7.2 based on its forward 12 month price to earnings (EPS) of $4.39 per share
Its Price to Book (P/B) ratio is 2.06 compared to its sector average of 3.53
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.